Anja Harder
study nurse
Medizinische Onkologie und Hämatologie · Dept. I
ETOP 25-23 ADOPT-lung
Dec 6, 2024An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC
Clinical Studies - Dec 6, 2024 - Dec 31, 2029
Ongoing
Project leader: Früh Martin
Members: Harder Anja, Müller Fiona
A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects with Advanced or Metastatic PD-L1 High (TPS ≥50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08) (Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)
Aug 13, 2024
Clinical Studies - Aug 13, 2024 - Dec 31, 2099
Ongoing
Project leader: Jörger Markus
Members: Harder Anja, Quinter Janine
A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy
Nov 3, 2023
Clinical Studies - Nov 3, 2023 - Dec 31, 2099
Ongoing
Project leader: Baumann Michael
Members: Harder Anja, Quinter Janine
A double-blind randomised phase III trial evaluating the efficacy of ADT +/- darolutamide in de novo metastatic prostate cancer patients with vulnerable functional ability and not elected for docetaxel or androgen receptor targeted agents
Oct 18, 2023
Clinical Studies - Oct 18, 2023 - Dec 31, 2099
Ongoing
Project leader: Fischer Stefanie
Members: Harder Anja, Quinter Janine
A PHASE IB/II RANDOMIZED, OPEN LABEL DRUG REPURPOSING TRIAL OF GLUTAMATE SIGNALING INHIBITORS IN COMBINATION WITH CHEMORADIOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GLUGLIO)
May 10, 2023Die Studie untersucht die Wirksamkeit einer Kombination der Studienmedikamente Gabapentin, Sulfasalazin und Memantin zusammen mit der Standardtherapie (Strahlentherapie und Chemotherapie mit Temozolomid). Alle drei Studienmedikamente hemmen an unters...
Clinical Studies - May 10, 2023 - Dec 31, 2030
Ongoing
Project leader: Hundsberger Thomas
Members: Harder Anja, Müller Fiona
A multicentre single-arm phase II trial of amivantamab, lazertinib plus bevacizumab in patients with EGFR-mutant advanced NSCLC with progression on previous third-generation EGFR-TKI
Mar 14, 2023Die klinische Studie AMAZE-lung ist für Patienten bestimmt, bei denen eine Art von Lungenkrebs diagnostiziert wurde, der als "fortgeschrittener nicht-kleinzelliger Lungenkrebs" bezeichnet wird. Der Lungenkrebs, der in dieser Studie behandelt wird, we...
Clinical Studies - Mar 14, 2023 - Dec 31, 2099
Ongoing
Project leader: Früh Martin
Members: Harder Anja, Quinter Janine
CA209-6K7 - Intrathecal administration of anti-PD1/anti-CTLA-4 in combination with systemic combination of anti-PD1/anti-CTLA-4 in patients with NSCLC without oncogenic driver mutation or melanoma and newly diagnosed leptomeningeal metastasis: a multicentric phase I study
Dec 9, 2022Die leptomeningeale Metastasierung ist eine bedrohliche Entwicklung einer Tumorerkrankung. Die Therapie dieser Komplikation ist nicht gut standardisiert. Umschriebene Tumorherde können bestrahlt werden, aber eine Bestrahlung des gesamten Kopfes und d...
Clinical Studies - Dec 9, 2022 - Dec 31, 2099
Ongoing
Project leader: Weindler Susanne
Members: Harder Anja, Quinter Janine
A phase 3 multicenter, randomized, prospective, open-label trial of ibrutinibmonotherapy versus fixed-duration venetoclax plus obinutuzumab versusfixed-duration ibrutinib plus venetoclax in patients with previously untreatedchronic lymphocytic leukemia (CLL)
Dec 16, 2021
Clinical Studies - Dec 16, 2021 - Dec 31, 2099
Ongoing
Members: Baumann Michael, Harder Anja, Quinter Janine
DS1062-A-U303 ( TROPION-lung07) A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or Without Platinum Chemotherapy, in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations TROPION-Lung07
Oct 8, 2021
Clinical Studies - Oct 8, 2021 - Dec 31, 2099
Ongoing
Project leader: Jörger Markus
Members: Harder Anja, Quinter Janine
Assessing a ctDNA and PET-oriented therapy in patients with DLBCL multicenter, open-label, phase II trial
Jun 8, 2021Despite advances in the clinical care of patients with DLBCL and in understanding the biology of this disease, cure rates have remained the same since the introduction of rituximab to CHOP chemotherapy, and RCHOP chemoimmunotherapy remains the standa...
Clinical Studies - Jun 8, 2021 - Dec 31, 2099
Ongoing
Project leader: Fehr Martin
Members: Harder Anja, Quinter Janine
Atezolizumab in combination with Bevacizumab and Chemotherapy versus Bevacizumab and Chemotherapy in recurrent ovarian cancer- a randomized Phase III trial An ENGOT Trial
Mar 4, 2021This study will evaluate the efficacy and safety of atezolizumab plus bevacizumab and chemotherapy compared with placebo plus bevacizumab and chemotherapy in patients with recurrent ovarian-, fallopian tube, or primary peritoneal cancer with 1st or 2...
Clinical Studies - Mar 4, 2021 - Dec 31, 2099
Ongoing
Project leader: Huober Jens
Members: Harder Anja, Quinter Janine
IPSEN F-FR-60000-023
Jul 17, 2020A Phase II Multicentre, Open-Labe- Study of Cabozantinib as 2nd Line Treatment in Subjects with unresectable, locally advanced Metastatic Renal Cell Carcinoma wiht a Clear- Cell Componentn who progressed after 1st Line Treatment with Checkpoint inhib...
Clinical Studies - Jul 17, 2020 - Dec 31, 2099
Ongoing
Project leader: Aeppli Stefanie
Members: Harder Anja, Müller Fiona
A Multicenter Phase III Randomized study with second line chemotherapy plus or minus Bevacizumab in patients with Platinum sensitive Epithelial ovarian cancer recurrence after a Bevacizumab/chemotherapy first line. MITO-16b, MANGO-OV2b
Jul 9, 2020
Clinical Studies - Jul 9, 2020 - Jun 21, 2023
Completed
Project leader: Weder Patrik
Members: Harder Anja, Quinter Janine
Open-label, non-randomized phase-1 study of liposomal doxorubicin TLD-1 in patients with advanced solid tumors
Oct 26, 2018In dieser Studie wird zum ersten Mal die Sicherheit und Wirksamkeit eines neuen Medikaments (Talidox) bei Menschen untersucht. Bei dem neuen Medikament handelt es sich um einen bekannten Wirkstoff, das Chemotherapeutikum Doxorubicin, welches in einer...
Clinical Studies - Oct 26, 2018 - Dec 22, 2023
Completed
Project leader: Hess Dagmar
Members: Harder Anja, Quinter Janine
ODM-201 maintenance therapy in patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with one novel hormonal agent first line and non-progressive disease after second line treatment with a taxane: A multicenter randomized double-blind placebo-controlled phase II trial
Mar 31, 2017
Clinical Studies - Mar 31, 2017 - Jun 6, 2024
Completed
Project leader: Fischer Stefanie
Members: Harder Anja, Quinter Janine
SAKK HOVON 135
Oct 27, 2016A randomized phase II multicenter study to assess the tolerability and efficacy of the addition of ibrutinib to 10-day decitabine in UNFIT (i.e. HCT-CI ≥ 3) AML and high risk myelodysplasia (MDS) (IPSS-R > 4.5) patients aged ≥ 66 years.
Clinical Studies - Oct 27, 2016 - Dec 31, 2099
Ongoing
Project leader: Früh Martin
Members: Harder Anja, Müller Fiona